Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xenon Pharma, a clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in the areas of pain, cardiometabolic disease, and diseases of iron metabolism, has appointed Tarek Mansour as executive vice president of research and development.
Subscribe to our email newsletter
Dr Mansour has spent nearly 25 years in the life sciences industry with positions at Biochem Pharma and Wyeth Pharmaceuticals. His most recent position at Wyeth Research was as VP of chemical sciences head over multiple research sites.
Simon Pimstone, president and CEO of Xenon, said: “We are delighted to welcome Tarek to the Xenon team. Tarek is a world-class R&D executive whose experience in discovering products, a number of which are now on the market, will further enhance Xenon’s capabilities.
“His successful careers at Biochem Pharma and Wyeth Pharmaceuticals (now Pfizer) have armed Tarek with best-in-class drug discovery and development practice and we are confident that Tarek will make a major contribution to Xenon’s future innovative R&D efforts.”